A citation-based method for searching scientific literature

Bruce A Perkins, Julio Rosenstock, Jay S Skyler, Lori M Laffel, David Z Cherney, Chantal Mathieu, Christianne Pang, Richard Wood, Ona Kinduryte, Jyothis T George, Jan Marquard, Nima Soleymanlou. Diabetes Care 2019
Times Cited: 2







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
Daniël H van Raalte, Petter Bjornstad, Frederik Persson, David R Powell, Rita de Cassia Castro, Ping Stella Wang, Minzhi Liu, Hiddo J L Heerspink, David Cherney. Diabetes Care 2019
7
100

Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
Thomas Danne, Jeremy Pettus, Andrea Giaccari, Bertrand Cariou, Helena Rodbard, Stuart A Weinzimer, Mireille Bonnemaire, Sangeeta Sawhney, John Stewart, Stella Wang,[...]. Diabetes Technol. Ther. 2019
3
50

SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease.
Aparna P Sajja, Amit K Dey, Avirup Guha, Youssef Elnabawi, Aditya A Joshi, Ankur Kalra. J. Cardiovasc. Pharmacol. Ther. 2019
3
50


Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.
David R Matthews, Qiang Li, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Mehul Desai, William R Hiatt, Mark Nehler, Elisa Fabbrini,[...]. Diabetologia 2019
29
50

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters,[...]. Diabetes Care 2018
55
50


Type 1 diabetes mellitus.
Anastasia Katsarou, Soffia Gudbjörnsdottir, Araz Rawshani, Dana Dabelea, Ezio Bonifacio, Barbara J Anderson, Laura M Jacobsen, Desmond A Schatz, Åke Lernmark. Nat Rev Dis Primers 2017
170
50



Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
68
50

Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
Claire Baker, Suman Wason, Phillip Banks, Sangeeta Sawhney, Anna Chang, Thomas Danne, Diane Gesty-Palmer, Jake A Kushner, Darren K McGuire, Frank Mikell,[...]. Diabetes Obes Metab 2019
6
50

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Thomas Danne, Bertrand Cariou, John B Buse, Satish K Garg, Julio Rosenstock, Phillip Banks, Jake A Kushner, Darren K McGuire, Anne L Peters, Sangeeta Sawhney,[...]. Diabetes Care 2019
19
50

Glycaemic variability: The under-recognized therapeutic target in type 1 diabetes care.
Emma G Wilmot, Pratik Choudhary, Lalantha Leelarathna, Mike Baxter. Diabetes Obes Metab 2019
3
50

Hyperglycemic crises in adult patients with diabetes.
Abbas E Kitabchi, Guillermo E Umpierrez, John M Miles, Joseph N Fisher. Diabetes Care 2009
559
50

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
619
50

Adjunct Therapy in Type 1 Diabetes: A Survey to Uncover Unmet Needs and Patient Preferences Beyond HbA1c Measures.
Jeremy H Pettus, Jake A Kushner, Virginia Valentine, Richard Wood, Christianne Pang, Sachin Paranjape, Rachele Berria, Antonio Deluzio, Steven E Edelman. Diabetes Technol. Ther. 2019
1
100

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari. Cardiovasc Diabetol 2019
18
50

Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison.
J A McKnight, S H Wild, M J E Lamb, M N Cooper, T W Jones, E A Davis, S Hofer, M Fritsch, E Schober, J Svensson,[...]. Diabet. Med. 2015
132
50

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N. Engl. J. Med. 2017
139
50

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.
B Zambrowicz, J Freiman, P M Brown, K S Frazier, A Turnage, J Bronner, D Ruff, M Shadoan, P Banks, F Mseeh,[...]. Clin. Pharmacol. Ther. 2012
137
50

Insights Into Patients' Experience With Type 1 Diabetes: Exit Interviews From Phase III Studies of Sotagliflozin.
Claire Ervin, Vijay N Joish, Emily Evans, Dana DiBenedetti, Matthew Reaney, Ronald Preblick, Rita Castro, Thomas Danne, John B Buse, Pablo Lapuerta. Clin Ther 2019
1
100

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode,[...]. Diabetes Care 2019
56
50

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N. Engl. J. Med. 2019
875
50

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
227
50

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Peter Ueda, Henrik Svanström, Mads Melbye, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Björn Pasternak. BMJ 2018
69
50

Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
Javed Butler, Faiez Zannad, David Fitchett, Bernard Zinman, Audrey Koitka-Weber, Maximilian von Eynatten, Isabella Zwiener, Jyothis George, Martina Brueckmann, Alfred K Cheung,[...]. Circ Heart Fail 2019
9
50

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.
Paola Fioretto, Stefano Del Prato, John B Buse, Ronald Goldenberg, Francesco Giorgino, Daniel Reyner, Anna Maria Langkilde, C David Sjöström, Peter Sartipy. Diabetes Obes Metab 2018
31
50

Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Fengxia Xiao, Joseph Zimpelmann, Hans-Juergen Woerle, Odd E Johansen, Uli C Broedl, Maximilian von Eynatten, Kevin D Burns. Kidney Int. 2014
61
50

Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes.
Petter Bjornstad, Lori Laffel, William V Tamborlane, Gudrun Simons, Stefan Hantel, Maximilian von Eynatten, Jyothis George, Jan Marquard, David Z I Cherney. Diabetes Care 2018
7
50

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
533
50

Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Yuliya Lytvyn, Lucas C Godoy, Rosalie A Scholtes, Daniël H van Raalte, David Z Cherney. Curr. Diab. Rep. 2019
3
50

Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Qiang Li, Meg Jardine, Richard Oh,[...]. J Am Soc Nephrol 2019
17
50

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
72
50

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Mikhail Kosiborod, Carolyn S P Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Jonathan Shaw, Navdeep Tangri, Su-Yen Goh, Marcus Thuresson, Hungta Chen,[...]. J. Am. Coll. Cardiol. 2018
140
50

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Mehul Desai, Qiang Li, Hsiaowei Deng,[...]. Circulation 2018
66
50

Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.
Michael Fralick, Sebastian Schneeweiss, Elisabetta Patorno. N. Engl. J. Med. 2017
99
50


Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.
Hsien-Yen Chang, Sonal Singh, Omar Mansour, Sheriza Baksh, G Caleb Alexander. JAMA Intern Med 2018
36
50

Real-World Effectiveness of Sodium Glucose Co-Transporter-2 Inhibitors in Japanese Patients with Diabetes Mellitus.
Yuichiro Ito, James Van Schyndle, Takuya Nishimura, Toshifumi Sugitani, Tomomi Kimura.  2019
2
50

Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
Subodh Verma, C David Mazer, Mohammed Al-Omran, Silvio E Inzucchi, David Fitchett, Uwe Hehnke, Jyothis T George, Bernard Zinman. Circulation 2018
53
50

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson,[...]. Circulation 2017
311
50

Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
Avivit Cahn, Cheli Melzer-Cohen, Rena Pollack, Gabriel Chodick, Varda Shalev. Diabetes Obes Metab 2019
16
50


Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging.
Kengo Kidokoro, David Z I Cherney, Andrea Bozovic, Hajime Nagasu, Minoru Satoh, Eiichiro Kanda, Tamaki Sasaki, Naoki Kashihara. Circulation 2019
38
50

Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study.
Zhong Yuan, Frank J DeFalco, Patrick B Ryan, Martijn J Schuemie, Paul E Stang, Jesse A Berlin, Mehul Desai, Norm Rosenthal. Diabetes Obes Metab 2018
54
50

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Yuliya Lytvyn, Petter Bjornstad, Jacob A Udell, Julie A Lovshin, David Z I Cherney. Circulation 2017
116
50

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
53
50


Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.
Harindra Rajasekeran, Heather N Reich, Michelle A Hladunewich, Daniel Cattran, Julie A Lovshin, Yuliya Lytvyn, Petter Bjornstad, Vesta Lai, Josephine Tse, Leslie Cham,[...]. Am. J. Physiol. Renal Physiol. 2018
21
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.